Ultragenyx Q2 revenue $214M, reiterates 2027 profitability goal
Ultragenyx (RARE) reported Q2 revenue of $214M and reiterated its 2027 profitability goal. The company said it won FDA approvals for FAYUVI and Genglycos, halted GTX-102 for Angelman after a failed Phase 3, and cut costs amid analyst downgrades.
Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE) reported Q2 revenue of $214M and reaffirmed its 2027 profitability goal. The company said it won FDA approvals for FAYUVI for MPS IIIA and Genglycos for GSD Ia. Ultragenyx also halted GTX-102 for Angelman after a failed Phase 3 and cut costs amid analyst downgrades.